The U.S. Food and Drug Administration (FDA) has approved use of the five-day, once-daily regimen of LEVAQUIN(R) (levofloxacin) 750 mg I.V. and oral, for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
"The availability of this high-dose, short-course antibiotic regimen provides clinicians with an important tool in the management of cUTI and AP," said Richard David, MD, FACS, Associate Clinical Professor of Urology, David Geffen School of Medicine at UCLA. "Patients do not always finish a longer course of antibiotics. A shorter course of antibiotic offers patients the convenience of five day, once-daily therapy."
0 comments :
Post a Comment